Jennifer S. Buell

Agenus (United States) — United States

Medicine · Health Sciences

14h-index1.9kcitations85works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(48), Monoclonal and Polyclonal Antibodies Research(43), Immunotherapy and Immune Responses(20), CAR-T cell therapy research(16), Peptidase Inhibition and Analysis(13)

Publications84 total

The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity
Cancer Immunology Research·2025
1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings
2025Open Access
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
Oncogene·2025· 5 citedOpen Access
Data from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S6 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S16 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S10 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S17 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S14 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S7 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S4 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S8 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S10 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S9 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S11 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S2 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S1 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S13 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Table S2 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
Supplementary Figure S8 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Robert B. Stein(23), Dhan Chand(18), David A. Savitsky(17), Nicholas S. Wilson(17), Jeremy D. Waight(13), Benjamin Morin(13), Randi B. Gombos(10), Antoine Tanne(10), Daniel L. Levey(9), Steven O’Day(9), Marc Van Dijk(9), Katherine L. Tucker(8), Breelyn A. Wilky(8), Olivia Huber(8), Margaret K. Wilkens(7), Sylvia Vincent(7), Marilyn Marques(7), Haiyong Han(7), C Galand(7), Joseph E. Grossman(7)